Author pages are created from data sourced from our academic publisher partnerships and public sources.
Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers.
BACKGROUND GPI 15715 (AQUAVAN injection) is a new water-soluble prodrug which is hydrolyzed to release propofol. The objectives of this first study in humans were to investigate the safety,… Expand
An Investigation of the Effectiveness of Exercise and Manual Therapy in Treating Symptoms of TMJ Osteoarthritis
- P. Nicolakis, E. Burak, +4 authors V. Fialka-Moser
- Cranio : the journal of craniomandibular practice
- 1 January 2001
ABSTRACT The background and purpose of this investigation was to evaluate the use of a treatment protocol which included active and passive jaw movements, manual therapy techniques, correction of… Expand
Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor.
- P. Majer, P. Jackson, +17 authors T. Tsukamoto
- Chemistry, Medicine
- Journal of medicinal chemistry
- 2 April 2003
A series of 2-(thioalkyl)pentanedioic acids were synthesized and evaluated as inhibitors of glutamate carboxypeptidase II (GCP II, EC 18.104.22.168). The inhibitory potency of these thiol-based compounds… Expand
AQUAVAN injection, a water-soluble prodrug of propofol, as a bolus injection: a phase I dose-escalation comparison with DIPRIVAN (part 1): pharmacokinetics.
BACKGROUND AQUAVAN Injection (AQ) (GPI 15715; Guilford Pharmaceutical Inc., Baltimore, MD) is a water-soluble prodrug of propofol (PropofolGPI). This study aimed to explore the pharmacokinetics of… Expand
In vitro residualization and binding of figitumumab radioimmunoconjugates
Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats
- M. Schywalsky, H. Ihmsen, +4 authors H. Schwilden
- European journal of anaesthesiology
- 1 March 2003
Background and objective: We studied the pharmacokinetics and pharmacodynamics of GPI 15715 (Aquavan® injection), a new water-soluble prodrug metabolized to propofol by hydrolysis. Methods: Nine… Expand
Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats: Retraction
A phase I study of [225Ac]-FPI-1434 radioimmunotherapy in patients with IGF-1R expressing solid tumors.
TPS3152Background: Type I insulin-like growth factor receptor (IGF-1R) is a transmembrane protein which is overexpressed in solid tumors including non–small cell lung, prostate, and breast cancers....
AQUAVANO((R)) injectjon, a water-soluble prodrug of propofol as a bolus injection: A phase I dose-escalation comparison with DIPRIVAN((R)) (Part 1) - Pharmacokinetics. Vol. 103